{"id":"NCT01321554","sponsor":"Eisai Inc.","briefTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-17","primaryCompletion":"2013-11-15","completion":"2019-03-19","firstPosted":"2011-03-23","resultsPosted":"2016-12-12","lastUpdate":"2023-06-22"},"enrollment":392,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Thyroid Cancer"],"interventions":[{"type":"DRUG","name":"Lenvatinib","otherNames":["Lenvatinib (Lenvima, E7080)"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lenvatinib","otherNames":["Lenvatinib (Lenvima, E7080)"]}],"arms":[{"label":"Lenvatinib (Randomization Phase)","type":"EXPERIMENTAL"},{"label":"Placebo (Randomization Phase)","type":"PLACEBO_COMPARATOR"},{"label":"Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)","type":"EXPERIMENTAL"},{"label":"Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years","effectByArm":[{"arm":"Randomization Phase: Lenvatinib 24 mg","deltaMin":18.3,"sd":null},{"arm":"Randomization Phase: Placebo","deltaMin":3.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":155,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","Czechia","Denmark","France","Germany","Italy","Japan","Poland","Portugal","Romania","Russia","South Korea","Spain","Sweden","Thailand","United Kingdom"]},"refs":{"pmids":["33637020","33611104","30471649","28237867","27548104","26426092","25671254"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":171,"n":261},"commonTop":["Diarrhoea","Hypertension","Decreased appetite","Weight decreased","Nausea"]}}